Mediolanum Farmaceutici, an Italian pharmaceutical company owned by the family of the founder Rinaldo Del Bono, is in talks with potential new financial partners who may support a new phase of business development,  Il Sole 24 Ore writes, adding that Ardian is said to be a favourite counterpart for the deal.
However Ardian might not be alone in studying the dossier as the Mediolanum Farmaceutici has many contacts with the private equity market. The company has been actually for years a minority shareholder in BFF Farmafactoring, a bank wth a specific focus in financing the pharma sector, that is now listed on the Italian Stock Exchange after having being in the portfolio of both Apax Partners and then of Centerbridge (see here a previous post by BeBeez). In Italy CVC is also quite active in the sector as it owns a majority stake in Recordati (see here a previous post by BeBeez) and in Doc Generici (see here a previous post by BeBeez), which was sold by Charterhouse in 2016.
Founded in Milan in 1972 and led by ceo Alessandro Del Bono, Mediolanum Farmaceutici reached 200 million euros in consolidated revenues in 2017, after 176.2 million euros in 2016, when it posted a 49.4 million euros ebitda and an 11.3 millions net profit, having also a positive net financial position of 27.5 million euros (see here an analyis by Leanus, after free registration and login).
